Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer
- PMID: 23948249
- DOI: 10.1016/j.biotechadv.2013.08.003
Highlights of recent developments and trends in cancer nanotechnology research--view from NCI Alliance for Nanotechnology in Cancer
Abstract
Although the incidence of cancer and cancer related deaths in the United States has decreased over the past two decades due to improvements in early detection and treatment, cancer still is responsible for a quarter of the deaths in this country. There is much room for improvement on the standard treatments currently available and the National Cancer Institute (NCI) has recognized the potential for nanotechnology and nanomaterials in this area. The NCI Alliance for Nanotechnology in Cancer was formed in 2004 to support multidisciplinary researchers in the application of nanotechnology to cancer diagnosis and treatment. The researchers in the Alliance have been productive in generating innovative solutions to some of the central issues of cancer treatment including how to detect tumors earlier, how to target cancer cells specifically, and how to improve the therapeutic index of existing chemotherapies and radiotherapy treatments. Highly creative ideas are being pursued where novelty in nanomaterial development enables new modalities of detection or therapy. This review highlights some of the innovative materials approaches being pursued by researchers funded by the NCI Alliance. Their discoveries to improve the functionality of nanoparticles for medical applications includes the generation of new platforms, improvements in the manufacturing of nanoparticles and determining the underlying reasons for the movement of nanoparticles in the blood.
Keywords: Alliance; Cancer; Nanotechnology.
© 2013.
Similar articles
-
The NCI Alliance for Nanotechnology in Cancer: achievement and path forward.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Sep-Oct;2(5):450-60. doi: 10.1002/wnan.98. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010. PMID: 20552623
-
Application of nanotechnology in cancer research: review of progress in the National Cancer Institute's Alliance for Nanotechnology.Int J Biol Sci. 2007 Jan 25;3(2):108-10. doi: 10.7150/ijbs.3.108. Int J Biol Sci. 2007. PMID: 17304339 Free PMC article. No abstract available.
-
Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer.ACS Nano. 2010 Feb 23;4(2):589-94. doi: 10.1021/nn100073g. ACS Nano. 2010. PMID: 20175564
-
Emerging implications of nanotechnology on cancer diagnostics and therapeutics.Cancer. 2006 Aug 1;107(3):459-66. doi: 10.1002/cncr.22035. Cancer. 2006. PMID: 16795065 Review.
-
National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Nov;11(6):e1570. doi: 10.1002/wnan.1570. Epub 2019 Jul 1. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019. PMID: 31257722 Free PMC article. Review.
Cited by
-
Nanoparticles of a Pyrazolo-Pyridazine Derivative as Potential EGFR and CDK-2 Inhibitors: Design, Structure Determination, Anticancer Evaluation and In Silico Studies.Molecules. 2023 Oct 25;28(21):7252. doi: 10.3390/molecules28217252. Molecules. 2023. PMID: 37959672 Free PMC article.
-
Nanotechnology in cancer diagnosis: progress, challenges and opportunities.J Hematol Oncol. 2019 Dec 17;12(1):137. doi: 10.1186/s13045-019-0833-3. J Hematol Oncol. 2019. PMID: 31847897 Free PMC article. Review.
-
Indocarbocyanine nanoparticles extravasate and distribute better than liposomes in brain tumors.J Control Release. 2022 Sep;349:413-424. doi: 10.1016/j.jconrel.2022.07.008. Epub 2022 Jul 14. J Control Release. 2022. PMID: 35817279 Free PMC article.
-
Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours.J Drug Target. 2019 Jun-Jul;27(5-6):690-698. doi: 10.1080/1061186X.2019.1566339. Epub 2019 Feb 4. J Drug Target. 2019. PMID: 30614276 Free PMC article.
-
A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.Molecules. 2019 Jun 29;24(13):2413. doi: 10.3390/molecules24132413. Molecules. 2019. PMID: 31261939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous